All In Biotech

Drug Trial Radar · NCT02132260

Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2%and the Naftin® Cream 2% in Patients With Tinea Pedis

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 890 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

890

Actual

Start

Aug 2013

Primary completion

Feb 2014

Study completion Mar 2014

Sponsor

Sponsor type
Industry
First posted
May 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the efficacy and safety of the test formulation of Naftifine Hydrochloride Cream 2% to Naftin® (Naftifine Hydrochloride) 2% Cream in a 6 week study in patients with tinea pedis.

Conditions

  • Tinea Pedis

Interventions

  • Naftifine Hydrochloride Cream 2%Drug

    Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks

  • Naftin® (Naftifine Hydrochloride) Cream 2%Drug

    Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.

  • Placebo Topical CreamDrug

    Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic CureTime frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.